Pliant Therapeutics (NASDAQ:PLRX - Get Free Report)'s stock had its "buy" rating reissued by research analysts at Needham & Company LLC in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $38.00 price target on the stock. Needham & Company LLC's target price suggests a potential upside of 168.55% from the company's previous close.
PLRX has been the topic of several other research reports. Royal Bank of Canada increased their price objective on shares of Pliant Therapeutics from $50.00 to $54.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 5th. HC Wainwright reiterated a "buy" rating and issued a $48.00 price target on shares of Pliant Therapeutics in a research report on Wednesday, February 28th. Ten investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Pliant Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $48.44.
View Our Latest Report on Pliant Therapeutics
Pliant Therapeutics Stock Performance
PLRX stock traded down $0.77 during trading on Wednesday, reaching $14.15. The stock had a trading volume of 343,371 shares, compared to its average volume of 395,410. The firm has a market cap of $852.40 million, a PE ratio of -5.03 and a beta of 1.12. The company has a current ratio of 17.72, a quick ratio of 17.72 and a debt-to-equity ratio of 0.02. The stock's 50 day moving average is $15.70 and its two-hundred day moving average is $15.83. Pliant Therapeutics has a 52 week low of $12.60 and a 52 week high of $30.85.
Insider Buying and Selling at Pliant Therapeutics
In other news, insider Hans Hull sold 9,786 shares of the stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $17.23, for a total value of $168,612.78. Following the completion of the sale, the insider now directly owns 185,069 shares of the company's stock, valued at $3,188,738.87. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, insider Hans Hull sold 9,786 shares of the company's stock in a transaction dated Wednesday, January 17th. The stock was sold at an average price of $17.23, for a total value of $168,612.78. Following the completion of the transaction, the insider now owns 185,069 shares of the company's stock, valued at $3,188,738.87. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Bernard Coulie sold 25,721 shares of Pliant Therapeutics stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $17.23, for a total value of $443,172.83. Following the sale, the chief executive officer now directly owns 316,382 shares in the company, valued at approximately $5,451,261.86. The disclosure for this sale can be found here. Insiders have sold 50,485 shares of company stock valued at $869,857 over the last 90 days. 5.60% of the stock is currently owned by corporate insiders.
Institutional Trading of Pliant Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Pliant Therapeutics by 97.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,529 shares of the company's stock valued at $27,000 after purchasing an additional 754 shares during the last quarter. Quest Partners LLC bought a new position in Pliant Therapeutics during the fourth quarter valued at approximately $37,000. US Bancorp DE grew its holdings in Pliant Therapeutics by 144.3% during the 2nd quarter. US Bancorp DE now owns 2,150 shares of the company's stock valued at $39,000 after buying an additional 1,270 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Pliant Therapeutics by 271.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,449 shares of the company's stock valued at $44,000 after buying an additional 1,790 shares in the last quarter. Finally, Osaic Holdings Inc. increased its stake in Pliant Therapeutics by 94.1% in the 2nd quarter. Osaic Holdings Inc. now owns 2,746 shares of the company's stock worth $50,000 after acquiring an additional 1,331 shares during the last quarter. 97.30% of the stock is currently owned by institutional investors.
About Pliant Therapeutics
(
Get Free Report)
Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.
See Also
Before you consider Pliant Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pliant Therapeutics wasn't on the list.
While Pliant Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
